NAD⁺ Reduction in Glutamatergic Neurons Induces Lipid Catabolism and Neuroinflammation in the Brain via SARM1
Advanced Science · 2026
DOI: 10.1002/advs.202509950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Zhen-Xian Niou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gill Institute for Neuroscience, Indiana University, Bloomington, USA. Hauptthemen laut MEDLINE: Neurons, Armadillo Domain Proteins, Lipid Metabolism, Cytoskeletal Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
NAD⁺ homeostasis is vital for neuronal health, as demonstrated by the opposing roles of nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2), a NAD⁺‐synthesizing enzyme, and sterile alpha and TIR motif‐containing protein 1 (SARM1), a NAD⁺ hydrolase. Neurodegenerative insults that decrease NMNAT2 activate SARM1, leading to axon loss. To understand how the NMNAT2–SARM1 axis influences brain energy metabolism, multi‐omics approaches are used to investigate the metabolic changes resulting from neuronal NMNAT2 loss. Loss of NMNAT2 in glutamatergic neurons leads to a significant metabolic shift in the cerebral cortex from glucose to lipid catabolism, reduced lipid abundance, and pronounced neurodegenerative phenotypes and motor behavioral deficits. These metabolic disturbances are accompanied by altered glial expression of enzymes regulating glucose and lipid metabolism, enhanced inflammatory signaling, and disrupted astrocytic transcriptomic profiles related to cholesterol synthesis and immune activation. Notably, SARM1 deletion in NMNAT2‐deficient mice restored lipid metabolism, astrocyte transcriptomic profiles, and mitigated neurodegeneration and motor behaviors. These findings suggest that neuronal NAD⁺ depletion triggers maladaptive, SARM1‐dependent metabolic reprogramming, shifting energy use from glucose to lipids, which in turn promotes inflammation and neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gill Institute for Neuroscience, Indiana University, Bloomington, USA.
- Department of Psychological and Brain Sciences, Indiana University, Bloomington, USA.
- Program in Neuroscience, Indiana University, Bloomington, USA.
- Department of Biology, Indiana University, Bloomington, USA.
- Department of Nutrition, Texas A&M University, College Station, USA.
ORCID-Profile: Zhen-Xian Niou, Hui-Chen Lu
Förderung
- NIDA NIH HHS
- NIH HHS
- NCATS NIH HHS
- NCI NIH HHS
- NINDS NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Niou, Z. X., Yang, S., Enriquez, A., Espinas, N. A., Sri, A., Hines, C. D., Tennessen, J. M., Wu, C. S., Huang, J. Y., & Lu, H. C. (2026). NAD⁺ Reduction in Glutamatergic Neurons Induces Lipid Catabolism and Neuroinflammation in the Brain via SARM1. Advanced Science. https://doi.org/10.1002/advs.202509950
Vancouver
Niou ZX, Yang S, Enriquez A, Espinas NA, Sri A, Hines CD, et al. NAD⁺ Reduction in Glutamatergic Neurons Induces Lipid Catabolism and Neuroinflammation in the Brain via SARM1. Advanced Science. 2026. doi:10.1002/advs.202509950
BibTeX
@article{Niou2026,
author = {Niou, Zhen-Xian and Yang, Sen and Enriquez, Andrea and Espinas, Nino A and Sri, Anoosha and Hines, Caliel D and Tennessen, Jason M and Wu, Chia-Shan and Huang, Jui-Yen and Lu, Hui-Chen},
title = {NAD⁺ Reduction in Glutamatergic Neurons Induces Lipid Catabolism and Neuroinflammation in the Brain via SARM1},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202509950}
}
EUVIMED